BTIG raised the firm’s price target on Xtant Medical to $3 from $2 and keeps a Buy rating on the shares. The company’s Q1 results were “encouraging” and driven by strength from the legacy Surgalign portfolio, the analyst tells investors in a research note. Now two-to-three quarters since the acquisition, Surgalign is contributing solidly in the hardware segment while Xtant has improved stem cell supply dynamics, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
- Xtant Medical’s Earnings at Risk: The Unhedged Perils of Currency Fluctuations
- Xtant Medical sees FY24 revenue $112M-$116M
- Xtant Medical reports Q4 EPS (3c) vs (2c) last year
- Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024